Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.48
CLDN's Cash to Debt is ranked lower than
62% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. CLDN: 5.48 )
Ranked among companies with meaningful Cash to Debt only.
CLDN' s 10-Year Cash to Debt Range
Min: 5.48  Med: 9999.00 Max: No Debt
Current: 5.48
F-Score: 1
Z-Score: -5.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -87.24
CLDN's ROE (%) is ranked lower than
77% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CLDN: -87.24 )
Ranked among companies with meaningful ROE (%) only.
CLDN' s 10-Year ROE (%) Range
Min: -320.68  Med: -320.68 Max: -320.68
Current: -87.24
ROA (%) -71.29
CLDN's ROA (%) is ranked lower than
78% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. CLDN: -71.29 )
Ranked among companies with meaningful ROA (%) only.
CLDN' s 10-Year ROA (%) Range
Min: -87.49  Med: -70.06 Max: -61.4
Current: -71.29
-87.49
-61.4
ROC (Joel Greenblatt) (%) -8135.18
CLDN's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. CLDN: -8135.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLDN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25840.98  Med: -9317.21 Max: -6183.38
Current: -8135.18
-25840.98
-6183.38
» CLDN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CLDN Guru Trades in Q1 2014

Steven Cohen 34,821 sh (New)
» More
Q4 2014

CLDN Guru Trades in Q4 2014

Steven Cohen 7,400 sh (New)
Jim Simons 21,600 sh (New)
» More
Q1 2015

CLDN Guru Trades in Q1 2015

George Soros 120,000 sh (New)
Jim Simons 298,300 sh (+1281.02%)
Steven Cohen Sold Out
» More
Q2 2015

CLDN Guru Trades in Q2 2015

Jim Simons Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CLDN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.66
CLDN's P/B is ranked higher than
98% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CLDN: 0.66 )
Ranked among companies with meaningful P/B only.
CLDN' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 6.5
Current: 0.66
0
6.5
EV-to-EBIT 0.44
CLDN's EV-to-EBIT is ranked higher than
95% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 27.86 vs. CLDN: 0.44 )
Ranked among companies with meaningful EV-to-EBIT only.
CLDN' s 10-Year EV-to-EBIT Range
Min: 0  Med: 0.00 Max: 0
Current: 0.44
Current Ratio 3.52
CLDN's Current Ratio is ranked lower than
56% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CLDN: 3.52 )
Ranked among companies with meaningful Current Ratio only.
CLDN' s 10-Year Current Ratio Range
Min: 2.83  Med: 12.56 Max: 19.55
Current: 3.52
2.83
19.55
Quick Ratio 3.52
CLDN's Quick Ratio is ranked lower than
53% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. CLDN: 3.52 )
Ranked among companies with meaningful Quick Ratio only.
CLDN' s 10-Year Quick Ratio Range
Min: 2.83  Med: 12.56 Max: 19.55
Current: 3.52
2.83
19.55

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.63
CLDN's Price/Net Cash is ranked higher than
100% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. CLDN: 0.63 )
Ranked among companies with meaningful Price/Net Cash only.
CLDN' s 10-Year Price/Net Cash Range
Min: 0.74  Med: 5.19 Max: 8.13
Current: 0.63
0.74
8.13
Price/Net Current Asset Value 0.61
CLDN's Price/Net Current Asset Value is ranked higher than
99% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. CLDN: 0.61 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLDN' s 10-Year Price/Net Current Asset Value Range
Min: 0.72  Med: 5.13 Max: 7.89
Current: 0.61
0.72
7.89
Price/Tangible Book 0.60
CLDN's Price/Tangible Book is ranked higher than
98% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. CLDN: 0.60 )
Ranked among companies with meaningful Price/Tangible Book only.
CLDN' s 10-Year Price/Tangible Book Range
Min: 0.7  Med: 5.08 Max: 7.76
Current: 0.6
0.7
7.76
Earnings Yield (Greenblatt) (%) 245.83
CLDN's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CLDN: 245.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLDN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -14.9  Med: 0.00 Max: 829.5
Current: 245.83
-14.9
829.5

Analyst Estimate

Dec15 Dec16
EPS($) -1.52 -0.94
EPS without NRI($) -1.52 -0.94

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:72C.Germany,
Celladon Corp was incorporated in California on December 21, 2000 and reincorporated in Delaware in April 2012. The Company is a clinical-stage biotechnology with industry expertise in the development of cardiovascular gene therapy. Its programs target sarco/endoplasmic reticulum Ca2+ -ATPase, or SERCA, enzymes, which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, which is a clinical syndrome characterized by poor heart function resulting in inadequate blood flow to meet the body's metabolic needs, as well as blood vessel health, diabetes and neurodegenerative diseases. SERCA2a, an enzyme that becomes deficient in patients with heart failure, was scientifically validated as a molecular target for heart failure in the 1990s and became a focus of internal discovery efforts for many large pharmaceutical companies. Its therapeutic portfolio includes both gene therapies and small molecule compounds targeting diseases characterized by SERCA enzyme deficiency. MYDICAR, its advanced product candidate, uses gene therapy to target SERCA2a. Its suppliers include Lonza and Novasep, for the manufacturing of its viral vectors and product candidates for clinical testing purposes. The Company expect to rely upon Lonza, Novasep, and/or other third parties to produce materials required for the commercial production of its product candidates and companion diagnostic. Its commercial strategy involving a progressive build out of commercial infrastructure in the United States covering key prescribers and centers of excellence is one that they can realistically pursue. The Company face potential competition from many different sources, including larger and funded pharmaceutical companies. Its competitors include Renova Therapeutics, NanoCor Therapeutics, Juventas Therapeutics, VentriNova and Beat BioTherapeutics. Biological products, including gene therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&C Act and the PHS Act and their corresponding regulations govern, among other things, the testing, manufacturing, safety, purity, potency, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products. The Company requires to obtain FDA approval before clinical testing of a biological product begins, and each clinical trial protocol for a gene therapy product is reviewed by the FDA and, in some instances, the U.S. National Institutes of Health, or NIH, through its Recombinant DNA Advisory Committee, or RAC.
» More Articles for NAS:CLDN

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Cellad Aug 07 2015 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency o Jul 16 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 

More From Other Websites
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celladon Corporation of Pendency of... Aug 26 2015
Law Offices of Howard G. Smith Announces That a Class Action Has Been Filed on Behalf of Celladon... Aug 26 2015
August 31 Deadline in Lawsuit for Investors in Celladon Corp (NASDAQ:CLDN) Shares Announced by... Aug 25 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Aug 24 2015
CELLADON CORP Financials Aug 22 2015
SECURITIES ALERT: The Rosen Law Firm Reminds Celladon Corporation Investors of the Important August... Aug 21 2015
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Aug 20 2015
GPM Announces the Filing of a Securities Class Action on Behalf of Celladon Corp. Investors Aug 19 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency... Aug 17 2015
CELLADON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 11 2015
Celladon Reports Second Quarter 2015 Financial Results Aug 11 2015
Celladon Reports Second Quarter 2015 Financial Results Aug 11 2015
CELLADON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Aug 11 2015
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving... Aug 10 2015
Q2 2015 Celladon Corp Earnings Release - Tentative - After Market Close Aug 10 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Aug 07 2015
SECURITIES ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit... Jul 31 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency... Jul 30 2015
Morgan & Morgan Reminds Investors That Class Action Lawsuits Have Been Filed Against Celladon... Jul 30 2015
LAWSUIT ALERT REMINDER: The Law Firm of Andrews & Springer LLC Announces That a Securities Fraud... Jul 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK